Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Elmiron-associated Retinopathy and Other Elmiron Eye Problem Side Effects

December 29, 2021 By Law Offices of Thomas J. Lamb, P.A.

For some important details about Elmiron-associated retinopathy and other Elmiron eye problem side effects, we point out this excerpt from the Discussion part of this recent Clinical Ophthalmology medical journal article, ” “Pentosan Polysulfate Sodium-Associated Pigmentary Retinopathy: Risk Factors and Fundus Findings”, which was published on … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Elmiron, maculopathy, pigmentary maculopathy, retinal pigmentary changes, retinopathy, vision loss

Elmiron and Maculopathy: Two Recent Medical Articles About an Elmiron Vision Side Effect

September 10, 2021 By Law Offices of Thomas J. Lamb, P.A.

In this post, we look at some relatively recent research regarding the still-emerging drug safety issue of Elmiron and maculopathy, i.e., maculopathy is an Elmiron vision side effect. According to “Screening needed for pentosan polysulfate sodium-associated maculopathy”, published on September 2, 2021, by Ocular Surgery News: In most cases, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Elmiron, maculopathy, pigmentary maculopathy, retinal pigmentary changes, vision loss

Drug Injury Lawsuits: List of Some Cases Filed in First Half of 2021

August 9, 2021 By Law Offices of Thomas J. Lamb, P.A.

A drug injury lawsuit is a personal injury case or a wrongful death case involving a serious drug side effect or a severe adverse drug reaction. Here are some of the prescription medications for which drug injury lawsuits were filed against the responsible pharmaceutical company in the first half of 2021: Xeljanz Beovu Elmiron … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Actemra, Belviq, Beovu, Elmiron, Farxiga, Injectafer, Invokana, Jardiance, Ocaliva, Tasigna, Uloric

New Elmiron Medication Guide Points Out Retinal Pigmentary Eye Problems

March 18, 2021 By Law Offices of Thomas J. Lamb, P.A.

The new Elmiron Medication Guide mandated by the FDA Center for Drug Evaluation and Research (CDER) in March 2021 follows and reiterates the June 2020 Elmiron label change that added warning about the pigmentary maculopathy Elmiron side effect. We point out that before the June 2020 Elmiron label change adding this new warning about the … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Elmiron, pigmentary maculopathy, vision loss

Some Information About Our Monthly Law Firm Newsletter

March 8, 2021 By Law Offices of Thomas J. Lamb, P.A.

The Lamb Law Office Newsletter is a monthly communication from our law firm to help keep you up to date with some of the cases that we are working on for clients at the present time. In addition, we provide at least one information resource item per month, which you or someone you know might find helpful from time to time. Past … [Read more...]

Filed Under: Uncategorized Tagged With: Asbestos Mesothelioma, Belviq, benzene, Beovu, breast implants, Elmiron, genx, Injectafer, Lamb Law Office Newsletter, Law Firm Newsletter, Monthly Newsletter, Newsletter, sglt2 inhibitors, Xeljanz

Elmiron Can Double the Risk of Pigmentary Maculopathy or Macular Degeneration

February 26, 2021 By Law Offices of Thomas J. Lamb, P.A.

Elmiron (pentosan polysulfate sodium, or PPS) was approved by the FDA way back in September 1996 for the treatment of painful bladder syndrome (interstitial cystitis). Over the past several years, however, cases of Elmiron-related eye damage have been reported. Remarkably, according to a recent medical study, patients with high levels of Elmiron … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug injury lawsuits, Elmiron, macular degeneration, pigmentary maculopathy, vision loss

Maculopathy Patients Should be Asked About Any Elmiron Use in Past

January 27, 2021 By Law Offices of Thomas J. Lamb, P.A.

A new Elmiron medical study about cases of macular toxicity related pentosan polysulfate (PPS) exposure suggests that established maculopathy patients should be questioned regarding any Elmiron use in the past. This will help eye doctors determine whether this person may have Elmiron maculopathy secondary to PPS toxicity. The findings of this … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blindness, Elmiron, maculopathy, pigmentary maculopathy, retinal maculopathy, vision loss

Elmiron Legal Cases for Eye Damage and Retinal Injury Are Consolidated in Elmiron MDL

January 15, 2021 By Law Offices of Thomas J. Lamb, P.A.

In December 2020, all Elmiron legal cases alleging eye damage and retinal injury filed in the federal courts were consolidated by means of an Elmiron MDL Order. These Elmiron legal cases are noteworthy as regards the monetary damages aspect of a lawsuit because these Elmiron-related eye problems can lead to vision loss or blindness. From the … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Elmiron, pigmentary maculopathy, retinal maculopathy, vision loss

Elmiron Updates: Legal, Medical, and Regulatory – December 2020

January 5, 2021 By Law Offices of Thomas J. Lamb, P.A.

In our final Drug Injury Watch article for 2020 we want to report on the recent developments regarding Elmiron lawsuits, Elmiron side effects warnings, and Elmiron pigmentary maculopathy diagnosis methods. As regards the increasing number of Elmiron lawsuits for patients who have suffered vision loss due to Elmiron pigmentary maculopathy, there … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Elmiron, pigmentary maculopathy, vision loss

Are Elmiron Side Effects Risks for Eye and Vision Are Greater Than Its Bladder Treatment Benefits?

September 15, 2020 By Law Offices of Thomas J. Lamb, P.A.

In the past few years, there are case reports of Elmiron (pentosan polysulfate sodium / “PPS”) causing eye problems such as retinal pigmentary changes and pigmentary maculopathy resulting in vision loss. The current body of medical literature suggests that perhaps Elmiron side effects risks related to the eye and vision — such as Elmiron-associated … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Elmiron, maculopathy, pigmentary maculopathy

  • 1
  • 2
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.